The CEO of Novo Nordisk, a major pharmaceutical company, has spoken out about the recent deaths linked to compounded versions of the diabetes drug semaglutide, which is also used for weight loss. Lars Fruergaard Jørgensen expressed concern over the lack of regulation surrounding compounded drugs and called for stricter oversight. Compounded drugs are custom-made medications that are not FDA-approved, and there have been reports of overdoses and deaths associated with compounded semaglutide. Jørgensen emphasized the importance of patient safety and urged authorities to take action to prevent further harm. He also reiterated Novo Nordisk’s commitment to providing safe and effective treatments through proper regulatory channels. The CEO’s comments highlight the ongoing debate around compounded drugs and the need for stricter quality control measures to protect public health.
Source: https://www.cnn.com/2024/11/06/health/compounded-semaglutide-deaths-novo-nordisk-ceo/index.html